Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent

American heart journal

Volumn 143, Issue 2, 2002, Pages 356-365

  Gouni Berthold, Ioanna ^a   Berthold, Heiner K ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Center for Cardiovascular Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FATTY ALCOHOL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; POLICOSANOL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DRUG INTERACTIONS; FATTY ALCOHOLS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; RANDOMIZED CONTROLLED TRIALS;

EID: 0036481621     PISSN: None     EISSN: 10976744     Source Type: Journal    
DOI: 10.1067/mhj.2002.119997     Document Type: Article

References (68)

1. WB Kannel WP Castelli T Gordon Lipoprotein cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Heart Study Ann Intern Med 90 1995 85 91
2. Expert Panel Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults Arch Intern Med 148 1988 36 69
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) JAMA 269 1993 3015 3023
4. AL Gould JE Rossouw NC Santanello Cholesterol reduction yields clinical benefit: a new look at old data Circulation 91 1995 2274 2282
5. CT Sempos JI Cleeman MD Carroll Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel JAMA 269 1993 3009 3014
6. TA Pearson I Laurora H Chu The lipid treatment assessment project (L-TAP)—a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
7. R Menendez SI Fernandez A Del Rio Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts Biol Res 27 1994 199 203
8. R Menendez AM Amor RM Gonzalez Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats Biol Res 29 1996 253 257
9. R Menendez L Arruzazabala R Mas Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet Br J Nutr 77 1997 923 932
10. WB Rizzo DA Craft AL Dammann Fatty alcohol metabolism in cultured human fibroblasts: evidence for a fatty alcohol cycle J Biol Chem 262 1987 17412 17419
11. K Ichihara E Kusunose Y Noda Some properties of the fatty alcohol oxidation system and reconstitution of microsomal oxidation activity in intestinal mucosa Biochim Biophys Acta 878 1986 412 418
12. N Kawamura HW Moser Y. Kishimoto Very long chain fatty acid oxidation in rat liver Biochem Biophys Res Commun 99 1981 1216 1225
13. H Singh N Derwas A. Poulos Very long chain fatty acid beta-oxidation by rat liver mitochondria and peroxisomes Arch Biochem Biophys 259 1987 382 390
14. R Menendez V Sotolongo V Fraga Plasma levels and excretion of total radioactivity in healthy volunteers after oral administration of 3H-octacosanol Rev CNIC Cien Biol 27 1996 32 35
15. VL Gonzales Canavaciolo J. Magraner Hernandez Validation of a gas chromatographic method for determining fatty alcohols that compose policosanol in five-milligram film-coated tablets J AOAC Int 82 1999 834 839
16. D Gonzales-Bravo J Magraner-Hernandez PC Acosta-Gonzales Analytical procedure for the determination of 1-octacosanol in plasma by solvent extraction and capillary gas chromatography J Chromatr 682 1996 359 363
17. Y Kabir S. Kimura Biodistribution and metabolism of orally administered octacosanol in rats Ann Nutr Metab 37 1993 33 38
18. MD Rodriguez H. Garcia Teratogenic and reproductive studies of policosanol in the rat and rabbit Teratog Carcinog Mutagen 14 1994 107 113
19. MD Rodriguez M Sanchez H. Garcia Multigenerational reproduction study of policosanol in rats Toxicol Lett 90 1997 97 106
20. MD Rodriguez H. Garcia Evaluation of peri- and post-natal toxicity of policosanol in rats Teratog Carcinog Mutagen 18 1998 1 7
21. R Zardoya L Tula G Castano Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function Curr Ther Res 57 1996 568 577
22. CL Aleman R Mas C Hernandez A 12 months study of policosanol oral toxicity in Sprague-Dawley rats Toxicol Lett 70 1994 77 87
23. P Pons M Rodriguez C Robaina Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment Int J Clin Pharm Res 14 1994 27 33
24. MM Canetti M Moreira R Mas Effects of policosanol on primary hypercholesterolemia: a 3-year openextension follow-up Curr Ther Res 58 1997 868 875
25. L Fernandez R Mas J Illnait Policosanol: results of a postmarketing surveillance study of 27,879 patients Curr Ther Res 59 1998 717 722
26. R Mas P Rivas JE Izquierdo Pharmacoepidemiologic study of policosanol Curr Ther Res 60 1999 458 467
27. F Hernandez J Illnait R Mas Effect of policosanol on serum lipids and lipoproteins in healthy volunteers Curr Ther Res 51 1992 568 575
28. P Pons R Mas J Illnait Efficacy and safety of policosanol in patients with primary hypercholesterolemia Curr Ther Res 52 1992 507 513
29. E Aneiros R Mas B Calderon Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia Curr Ther Res 56 1995 176 182
30. E Aneiros B Calderon R Mas Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment Curr Ther Res 54 1993 304 312
31. P Pons M Rodriguez R Mas One year efficacy and safety of policosanol in patients with type II hypercholesterolemia Curr Ther Res 55 1994 1084 1092
32. M Canetti M Moreira J Illnait One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia Adv Ther 12 1995 245 254
33. M Canetti M Moreira R Mas A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia Int J Clin Pharm Res 15 1995 159 165
34. G Castano R Mas JC Fernandez A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk Curr Ther Res 60 1999 379 391
35. G Castano R Mas L Fernandez Effects of policosanol on postmenopausal women with type II hypercholesterolemia Gynecol Endocrinol 14 2000 187 195
36. O Torres AJ Agramonte J Illnait Treatment of hypercholesterolemia in NIDDM with policosanol Diabetes Care 18 1995 393 396
37. N Crespo R Alvarez R Mas Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study Curr Ther Res 58 1997 44 51
38. G Castano L Tula M Canetti Effects of policosanol in hypertensive patients with type II hypercholesterolemia Curr Ther Res 57 1996 691 699
39. G Castano M Canetti M Moreira Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study Curr Ther Res 56 1995 819 828
40. R Mas G Castano J Illnait Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors Clin Pharmacol Ther 65 1999 439 447
41. G Ortensi J Gladstein H Valli A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia Curr Ther Res 58 1997 390 401
42. M Benitez C Romero R Mas A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia Curr Ther Res 58 1997 859 867
43. G Castano R Mas MdL Arruzazabala Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients Int J Clin Pharm Res 19 1999 105 116
44. N Crespo J Illnait R Mas Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus Int J Clin Pharm Res 19 1999 117 127
45. G Castano R Mas JC Fernandez Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors Curr Ther Res 61 2000 137 146
46. S Marcello J Gladstein P Tesone Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: a pilot study Curr Ther Res 61 2000 346 357
47. J Batista R Stüsser F Saez Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients: a 14-month pilot study Int J Clin Pharm Ther 34 1996 134 137
48. R Stüsser J Batista R Padron Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients Int J Clin Pharm Ther 36 1998 469 473
49. J Batista RJ Stüsser R Padron Functional improvement in coronary artery disease after 20 months of lipid-lowering therapy with policosanol Adv Ther 13 1996 137 148
50. G Castano R Mas JC Fernandez Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk J Gerontol A Biol Sci Med Sci 56 2001 M186 M192
51. J Batista R Stüsser M Penichet Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotoid-vertebral atherosclerosis Curr Ther Res 56 1995 906 914
52. M Saint-John L. McNaughton Octacosanol ingestion and its effects on metabolic responses to submaximal cycle ergometry reaction time and chest and grip strength Int Clin Nutr Rev 6 1986 81 87
53. G Castano R Mas J Roca A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication Angiology 50 1999 123 130
54. G Castano R Mas Ferreiro L Fernandez A long-term study of policosanol in the treatment of intermittent claudication Angiology 52 2001 115 125
55. M Noa R Mas MC de la Rosa Effect of policosanol on lipofundin-induced lesions in rats J Pharm Pharmacol 47 1995 289 291
56. M Noa MC de la Rosa R. Mas Effect of policosanol on foam-cell formation in carrageenan-induced granulomas in rats J Pharm Pharmacol 48 1996 306 309
57. M Noa R Mas R. Mesa Effect of policosanol on intimal thickening in rabbit cuffed carotid artery Int J Cardiol 67 1998 125 132
58. V Fraga R Menendez AM Amor Effect of policosanol on in vivo and in vitro rat liver microsomal lipid peroxidation Arch Med Res 28 1997 355 360
59. R Menendez R Mas AM Amor Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro Br J Clin Pharmacol 50 2000 255 262
60. ML Arruzazabala D Carbajal R Mas Effects of policosanol on platelet aggregation in rats Thromb Res 69 1992 321 327
61. 2 Prostaglandin Leukot Essent Fatty Acids 49 1993 695 697
62. D Carbajal ML Arruzazabala R Mas Effect of policosanol on experimental thrombosis models Prostaglandin Leukot Essent Fatty Acids 50 1994 249 251
63. V Molina ML Arruzazabala D Carbajal Effect of policosanol on cerebral ischemia in Mongolian gerbils Braz J Med Biol Res 32 1999 1269 1276
64. ML Arruzazabala S Valdes R Mas Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers Pharmacol Res 34 1996 181 185
65. S Valdes ML Arruzazabala L Fernandez Effect of policosanol on platelet aggregation in healthy volunteers Int J Clin Pharm Res 16 1996 67 72
66. ML Arruzazabala R Mas V Molina Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients Int J Tissue React 20 1998 119 124
67. ML Arruzazabala S Valdes R Mas Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers Pharmacol Res 36 1997 293 297
68. D Carbajal ML Arruzazabala S Valdes Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers Prostaglandin Leukot Essent Fatty Acids 58 1998 61 64